Skip to main content
. Author manuscript; available in PMC: 2021 Apr 15.
Published in final edited form as: Bioconjug Chem. 2020 Mar 20;31(4):1144–1155. doi: 10.1021/acs.bioconjchem.0c00003

Figure 5.

Figure 5.

Characterization of nanobodies as drug targeting agents. (a) Depiction of the hypothesized conjugate structure. Binding affinity of (b) VCAMelid-SOD conjugates and (c) VCAM/ALB8-SOD conjugates. (d) Whole-body biodistribution of VCAMelid-SOD conjugates, (e) blood pharmacokinetics of VCAMelid-SOD and VCAM/ALB8-SOD conjugates in TNF-a injected mice, and (f) biodistribution of VCAM-SOD and VCAM/ALB8-SOD conjugates in brain. All biodistributions were performed 20 min post-injection of equimolar doses of VCAMelid-SOD (10 μg) or VCAM/ALB8-SOD (16 μg) conjugates.